We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » GPhA WANTS CLARITY ON CORRECTING PATENTS, DEFINING 'LISTED DRUG'
GPhA WANTS CLARITY ON CORRECTING PATENTS, DEFINING 'LISTED DRUG'
May 13, 2004
The Generic Pharmaceutical Association (GPhA) wants the FDA to add regulatory language that would expressly require a brand firm to correct or delete patent information in the agency's Orange Book when a court order requires patent changes.